) What’s happening: Q2 profit rose 14% YoY to ₹1,437 cr; revenue up 10%. Strength from India & branded markets, mild US pressure. Why it matters: Consistent growth and product diversification help it withstand US generic volatility. Key takeaway: Pharma stock showing steady growth — good to study “defensive momentum” and earnings stability. Key levels: Support: ₹6,050 Resistance: ₹6,350 / ₹6,480 Breakout Zone: Above ₹6,500 could continue the uptrend Final Verdict: Stable to bullish; breakout above ₹6,500 may attract more buyers.

#FundamentalViews#TechnicalViews#StockInNews

475 likes·67 comments